NCT06783309 - CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Type 1 Diabetes MellitusT1DT1DMT1DM - Type 1 Diabetes MellitusType 1 Diabetes in AdolescenceType 1 Diabetes in ChildrenType 1 Diabetes (Juvenile Onset)Type 1 DiabetesType 1 Diabetes PatientsType 1 Diabetes Mellitis

Interventions

DRUG

CNP-103

DRUG

Placebo

0.9% sodium chloride for injection

Trial Locations (18)

11791

RECRUITING

MainStreet Health, Syosset

21229

RECRUITING

Barry J. Reiner, MD, LLC, Baltimore

27577

RECRUITING

Superior Clinical Research, Smithfield

27612

RECRUITING

Wake Research - Raleigh, Raleigh

27834

RECRUITING

Physicians East, PA, Greenville

33176

RECRUITING

DY Professional Research Center, Miami

55454

RECRUITING

University of Minnesota, Minneapolis

75224

RECRUITING

Wake Research - Dallas, Dallas

75231

RECRUITING

Revival Research Institute - Dallas, Dallas

76210

RECRUITING

Revival Research Institute - Denton, Denton

77082

RECRUITING

Zillan Clinical Research, Houston

77346

RECRUITING

Accurate Clinical Research, Inc, Humble

78229

RECRUITING

Diabetes & Glandular Disease (DGD) Clinic, P.A., San Antonio

78749

RECRUITING

Texas Diabetes & Endocrinology, Austin

80045

RECRUITING

Barbara Davis Center for Childhood Diabetes, Aurora

85710

RECRUITING

Wake Research - Tucson, Tucson

90806

RECRUITING

Long Beach Clinical Trials, Inc, Long Beach

94598

RECRUITING

Diablo Clinical Research, Walnut Creek